Consulting for large and small pharmaceutical and biotechnology companies in the areas ofdevelopment strategy, project leadership, expanded access programs, clinical research & development, medical affairs strategy including asset development plans and evidence generation plans, medical monitoring, compliance and operations.
• Head ofMedical Affairs for a small biotech company, developed and implemented peri-launch & pre launch strategies.
• Developed strategic plans and managed the execution of4 global Early Access Programs for hematol ogy & oncology products throughout their lifecycle.
• Experienced project manager in developing and implementing grant management solutions, clinical trials, and comprehensive cross-functional strategic plans.
• Developed a comprehensive evidence generation plan with cross-functional stakeholders.

Global Strategic Development & Education, Medical Affairs, Inflammation & Immunology
• Established and provided strategic leadership for the Global Medical Affairs organization by: Ø Developing annual strategic plans in collaboration with other functions including Clinical, Com mercial & HEOR, and in compliance with corporate policies and regulatory requirements. Ø Guiding strategic direction for development and lifecycle management activities to ensure smooth transition from clinical development to commercialization. Ø Driving innovative concepts and ideas to identify new medical applications for patients.
• Acted as a key strategic partner to the Global Medical Affairs I&I Business Unit leaders ensuring med ically sound promotional positioning, clear and relevant promotional and medical materials, and strate gically aligned commercial and medical plans. Provided support and guidance to key asset and product decisions by taking into consideration specific commercial contexts and inp

Lead and managed multiple medical liaison teams responsible for: 63 medical liaison staff (rheumatol ogy/dermatology, gastroenterology, neurology, managed care and training); key opinion leader strategy & development; product launches, oversight ofphase IV clinical trial plans for I&I's marketed product(s); over sight ofcontinuing medical education initiatives; and global sales force and supplier training.
• Developed and drove the I&I US Medical Affairs short and long-term strategies that: Ø Ensured all I&I Medical Affairs activities were fully aligned with the I&I Commercial and Clinical Research Strategies Ø Reflected appropriate input from the global medical community Ø Ensured suitable coverage of aspects of medical practice and patient management, drug combina tions, health economics and outcome research
• Increased clinical trial enrollment by 75% by partnering with clinical and deploying medical affairs to assist with trial education and recruitment.
• Ensured appropriate me

• Developed and lead the implementation of RML Medical Affairs strategy for the Immunology & Inflammation franchise.
• Created a streamlined recruiting/hiring strategy effective in hiring high quality team consisting of 4 Regional Directors plus 15 Regional Medical Liaisons in North America within seven months.
• Managed field training, evaluation, motivation and disciplinary activities in alignment with Celgene corporate strategies and objectives.
• Conducted periodic reality based, results focused operating reviews and drove appropriate change and adjustment to ensure desired alignment and execution of strategies.

• Developed and lead the implementation ofRML Medical Affairs strategy for the Immunology & Inflammation franchise.
• Created a streamlined recruiting/hiring strategy effective in hiring high quality team consisting of4 Regional Directors plus 15 Regional Medical Liaisons in North America within seven months.
• Managed field training, evaluation, motivation and disciplinary activities in alignment with Celgene corporate strategies and objectives.
• Conducted periodic reality based, results focused operating reviews and drove appropriate change and adjustment to ensure desired alignment and execution ofstrategies.

• Managed and provided leadership and direct supervision of6 Clinical Science Liaisons nationwide.
• Assessed individual CSL needs for professional development and provide coaching, mentoring and train ing.
• Participated in project and committee teams, as well as majormedicalmeetings serving as key clinical liaison in respective defined clinical field.

• Managed and planned the execution and reporting of Apremilast clinical trials in the Clinical Science Liaison Immunology & Inflammation program.
• Developed and managed standard program processes including clinical development plans, clinical pro tocols, budgets, and data documentation systems and reporting.
• Participated in project and committee teams serving as key clinical liaison with Quality Assurance and the Clinical Development program. 4
● Clinical Science Liaison, Inflammation & Immunology Clinical Science Liaison, Hematology & Oncology
● • Cultivated collaborative relationships with current and future thought leaders in academic and clinical medicine at the local, regional and national levels.
• Initiated and implemented Phase II/III/IV protocols in target disease states of mutual interest at key institutions and developed publication strategies once trials completed.
• Negotiated terms and conditions of protocols, consents, contracts and budgets with healthcare pro